Revive Therapeutics Aims to Bring Psychedelics to Market
February 17th, 2021
App, Exclusive, Psychedelics, Top News
The psychedelic drug market is projected to grow at a 16.3% compound annual growth rate to reach nearly $7 billion by 2027, according to Data Bridge Market Research. While there are a growing number of publicly traded companies in the space, the best opportunities have the right combination of experience, intellectual property and clinical trials.
Let’s take a closer look at Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) and how its robust IP portfolio and well-funded clinical trials could generate near-term shareholder value.
Robust Technology & IP Portfolio
Revive Therapeutics has built an in-house patent portfolio covering psilocybin methods and compositions, as well as drug delivery systems. In particular, they cover capsules, sublingual sprays, gel caps, effervescent tablets and oral strips, which improve bioavailability, enable precise dosing, and ultimately, create a better doctor and patient experience.
For example, the company is working with researchers at the University of Wisconsin to develop a tannin-chitosan composite of orally dissolvable thin films to deliver up to 20mg of psilocybin into the oral cavity. The delivery system offers a number of benefits over conventional delivery mechanisms and creates a patentable psilocybin product.
The oral thin strips rapidly dissolve into the bloodstream and are more convenient than pills because they don’t require water, chewing or swallowing. In addition, the delivery technology has the potential for a controlled or sustained release over time, as well as the ability to combine multiple extracts from mushrooms in one formulation.
Well-Funded with Clinical Trials
Revive Therapeutics recently raised $20 million in a bought deal offering to fund Phase I clinical trial for psilocybin for methamphetamine use disorder and other psychedelic formulation development work, as well as for their Phase 3 trial with Bucillamine to treat Covid 19.
The National Survey on Drug Use and Health found that 1.6 million people have used methamphetamine and nearly one million have methamphetamine use disorder—and these numbers are on the rise. According to Reports and Data, the market for drug addiction treatments will rise from $16.5 billion in 2018 to $31 billion by 2027.
The company is also conducting preclinical studies of an oral formulation of psilocybin for the treatment of depression, anxiety and other mental health conditions. As other psychedelic research has confirmed, psilocybin could play a central role in the treatment of a wide range of mental health disorders with fewer side-effects than existing treatment options.
The market for depression, anxiety and other mental health disorders is potentially much larger than substance abuse treatments. According to Grand View Market Research, the global anxiety disorders and depression treatment market will grow from $15.2 billion in 2015 to $18.3 billion by 2025, but could be significantly larger if psychedelics prove effective.
Revive Therapeutics represents a unique opportunity to invest in the psychedelics space with a robust IP portfolio, unique delivery technologies and ongoing clinical trials that are well funded.
For more information, visit the company’s website
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.